Navigation Links
ProMIS Neurosciences issues white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach”
Date:2/22/2017

ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.” This is one of a series of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio and Alzheimer’s disease (AD) science in the popular press.

The white paper discusses the recent late-stage clinical trial failures of Eli Lilly’s solanezumab, a monoclonal antibody (mAb) mainly targeting Amyloid beta (Aß monomers, and Merck’s verubecestat, a small molecule BACE inhibitor that blocks the cleavage of amyloid precursor protein, thereby significantly reducing the formation of Aß monomers in the brain.

Commenting on the results of the failed clinical trials, Dr. Johanne Kaplan, ProMIS Chief Development Officer stated, “Both approaches, which mainly target Aß monomers failed to show clinically significant cognitive benefit as they failed to engage toxic Aß oligomers, which propagate in a prion-like manner and are the primary drivers of neurodegeneration and cognitive decline in AD patients.”

Conversely, Biogen’s monoclonal antibody aducanumab, which binds Aß oligomers and plaque, reduced cognitive decline in a Phase 1b trial. Binding to plaque however, was associated with dose-dependent toxicity (brain edema, or ARIA-E), which limits the therapeutic window for this antibody.

The white paper concludes that human clinical data to date are supportive of the ProMIS approach of selectively targeting soluble toxic Aß oligomers. “We believe our approach will lead to best in class therapy as selectively targeting the toxic prion-like Aß oligomers maximizes efficacy by avoiding off target binding to non-pathogenic Aß monomers, and decreases the risk of edema and vascular adverse events associated with plaque binding,” stated Dr. Elliot Goldstein, ProMIS President & CEO.

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,
and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, and to access the white paper, please consult the Company's website at:
http://www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

NATIONAL Equicom
Abby Garfunkel
Tel. 403-218-2887
agarfunkel(at)national(dot)ca

or contact

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences(dot)com

Read the full story at http://www.prweb.com/releases/2017/02/prweb14089747.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. ProMetics PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome
2. ProMIS Neurosciences Declares PMN 310 its First Lead Product for Development in Alzheimer’s Disease
3. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
4. ProMIS Neurosciences Announces Novel Alzheimer’s Disease Therapeutic Candidates Block the Neurotoxicity of Prion-Like Forms of Amyloid Beta
5. Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery
6. ProMIS Neurosciences announces five novel Alzheimer’s disease therapeutic candidates block spreading of toxic prion-like forms of Amyloid beta
7. Promising New Prostate Cancer Tests On The Horizon - Dr. David Samadi
8. PrecisionAg® Media’s New Vision Accelerates the Promise of Technology-Driven Agriculture
9. ProMIS Neurosciences Announces Identification of a Fourth Novel Therapeutic Target for Alzheimer’s Disease
10. Communications Among Most Promising Applications for Game-Changing Graphene
11. ProMIS Neurosciences, Inc. Completes First Tranche of its Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The latest generation of ... of sample prep for metals digestion—the addition of acids and reagents. The accessory ... The system is ideal for any laboratory performing their own unique metals digestion ...
(Date:9/19/2017)... ... September 19, 2017 , ... One ... about to be eliminated, said Lyle Probst, President, CEO and Founder of ... different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside ...
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, ... applications, announced today that two new patents have been allowed by the USPTO ... of Band-LOK, said, “We continue to explore additional clinically-relevant designs for both the ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne ... Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application ... East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second clinical ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):